;PMID: 7423654
;source_file_997.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:48..122] = [t:48..122]
;2)section:[e:126..172] = [t:126..172]
;3)sentence:[e:176..344] = [t:176..344]
;4)sentence:[e:345..396] = [t:345..396]
;5)sentence:[e:397..548] = [t:397..548]
;6)sentence:[e:549..732] = [t:549..732]
;7)sentence:[e:734..867] = [t:734..867]
;8)sentence:[e:868..965] = [t:868..965]
;9)sentence:[e:967..1121] = [t:967..1121]
;10)sentence:[e:1123..1184] = [t:1123..1184]
;11)sentence:[e:1185..1316] = [t:1185..1316]
;12)section:[e:1320..1364] = [t:1320..1364]

;section 0 Span:0..42
;Undersea Biomed Res. 1980 Sep;7(3):161-70.
(SEC
  (FRAG (NNP:[0..8] Undersea) (NNP:[9..15] Biomed) (NNP:[16..19] Res)
        (IN:[19..20] .) (CD:[21..25] 1980) (CC:[26..32] Sep;7-LRB-)
        (CD:[32..33] 3) (-RRB-:[33..34] -RRB-) (CD:[34..38] :161) (::[38..39] -)
        (CD:[39..41] 70) (.:[41..42] .)))

;sentence 1 Span:48..122
;In vivo and in vitro induction of cytochrome P-450 synthesis in hyperoxia.
;[82..98]:cyp450:"cytochrome P-450"
(SENT
  (NP-HLN
    (NP
      (NP
        (ADJP (FW:[48..50] In) (FW:[51..55] vivo))
        (NML-1 (-NONE-:[55..55] *P*)))
      (CC:[56..59] and)
      (NP
        (ADJP (FW:[60..62] in) (FW:[63..68] vitro))
        (NML-1 (NN:[69..78] induction))))
    (PP (IN:[79..81] of)
      (NP
        (NML (NN:[82..92] cytochrome) (NN:[93..98] P-450))
        (NN:[99..108] synthesis)))
    (PP (IN:[109..111] in)
      (NP (NN:[112..121] hyperoxia)))
    (.:[121..122] .)))

;section 2 Span:126..172
;Longmuir IS, Gottlieb SF, Pashko LL, Martin P.
(SEC
  (FRAG (NNP:[126..134] Longmuir) (NNP:[135..137] IS) (,:[137..138] ,)
        (NNP:[139..147] Gottlieb) (NNP:[148..150] SF) (,:[150..151] ,)
        (NNP:[152..158] Pashko) (NNP:[159..161] LL) (,:[161..162] ,)
        (NNP:[163..169] Martin) (NNP:[170..172] P.)))

;sentence 3 Span:176..344
;Exposure of dark- or light-adapted mice to 1--3 ATA oxygen for times ranging 
;from 15 min to 4 h caused a progressive increase in P-450, which peaked and
;then  decayed.
;[219..223]:quantitative-value:"1--3"
;[224..227]:quantitative-units:"ATA"
;[228..234]:substance:"oxygen"
;[259..261]:quantitative-value:"15"
;[262..265]:quantitative-units:"min"
;[269..270]:quantitative-value:"4"
;[271..272]:quantitative-units:"h"
;[306..311]:cyp450:"P-450"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[176..184] Exposure))
      (PP (IN:[185..187] of)
        (NP
          (NP
            (ADJP (NN:[188..192] dark) (HYPH:[192..193] -)
              (ADJP-2 (-NONE-:[193..193] *P*)))
            (NML-3 (-NONE-:[193..193] *P*)))
          (CC:[194..196] or)
          (NP
            (ADJP (NN:[197..202] light) (HYPH:[202..203] -)
              (ADJP-2 (VBN:[203..210] adapted)))
            (NML-3 (NNS:[211..215] mice)))))
      (PP (TO:[216..218] to)
        (NP
          (NML
            (QP (CD:[219..220] 1) (SYM:[220..222] --) (CD:[222..223] 3))
            (NN:[224..227] ATA))
          (NN:[228..234] oxygen)))
      (PP (IN:[235..238] for)
        (NP
          (NP (NNS:[239..244] times))
          (VP (VBG:[245..252] ranging)
            (PP (IN:[254..258] from)
              (NP (CD:[259..261] 15) (NN:[262..265] min)))
            (PP (TO:[266..268] to)
              (NP (CD:[269..270] 4) (NN:[271..272] h)))))))
    (VP (VBD:[273..279] caused)
      (NP
        (NP
          (NP (DT:[280..281] a) (JJ:[282..293] progressive)
              (NN:[294..302] increase))
          (PP (IN:[303..305] in)
            (NP (NN:[306..311] P-450))))
        (,:[311..312] ,)
        (SBAR
          (WHNP-1 (WDT:[313..318] which))
          (S
            (NP-SBJ-1 (-NONE-:[318..318] *T*))
            (VP (VBD:[319..325] peaked)
              (CONJP (CC:[326..329] and) (RB:[330..334] then))
              (VBD:[336..343] decayed))))))
    (.:[343..344] .)))

;sentence 4 Span:345..396
;The rate of decay appears to be independent of PO2.
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[345..348] The) (NN:[349..353] rate))
      (PP (IN:[354..356] of)
        (NP (NN:[357..362] decay))))
    (VP (VBZ:[363..370] appears)
      (S
        (NP-SBJ-1 (-NONE-:[370..370] *))
        (VP (TO:[371..373] to)
          (VP (VB:[374..376] be)
            (ADJP-PRD (JJ:[377..388] independent)
              (PP (IN:[389..391] of)
                (NP (NN:[392..395] PO2))))))))
    (.:[395..396] .)))

;sentence 5 Span:397..548
;A linear, inverse  relationship was noted between the PO2 in the range of
;1--4 ATA and the duration  of exposure needed to obtain maximum P-450
;levels.
;[471..475]:quantitative-value:"1--4"
;[476..479]:quantitative-units:"ATA"
;[535..540]:cyp450:"P-450"
(SENT
  (S
    (NP-SBJ-1 (DT:[397..398] A) (JJ:[399..405] linear) (,:[405..406] ,)
              (JJ:[407..414] inverse) (NN:[416..428] relationship))
    (VP (VBD:[429..432] was)
      (VP (VBN:[433..438] noted)
        (NP-1 (-NONE-:[438..438] *))
        (PP (IN:[439..446] between)
          (NP
            (NP
              (NP (DT:[447..450] the) (NN:[451..454] PO2))
              (PP (IN:[455..457] in)
                (NP
                  (NP (DT:[458..461] the) (NN:[462..467] range))
                  (PP (IN:[468..470] of)
                    (NP
                      (QP (CD:[471..472] 1) (SYM:[472..474] --)
                          (CD:[474..475] 4))
                      (NN:[476..479] ATA))))))
            (CC:[480..483] and)
            (NP
              (NP
                (NP (DT:[484..487] the) (NN:[488..496] duration))
                (PP (IN:[498..500] of)
                  (NP (NN:[501..509] exposure))))
              (VP (VBN:[510..516] needed)
                (S
                  (NP-SBJ (-NONE-:[516..516] *))
                  (VP (TO:[517..519] to)
                    (VP (VB:[520..526] obtain)
                      (NP (JJ:[527..534] maximum) (NN:[535..540] P-450)
                          (NNS:[541..547] levels)))))))))))
    (.:[547..548] .)))

;sentence 6 Span:549..732
;Cytochrome P-450 was induced  by hyperoxia in vitro in a suspension of
;hepatocytes, and this induction was  prevented by inhibitors of transcription
;and translation and by disulfiram.
;[549..565]:cyp450:"Cytochrome P-450"
;[670..680]:substance:"inhibitors"
;[721..731]:substance:"disulfiram"
(SENT
  (S
    (S
      (NP-SBJ-1 (NN:[549..559] Cytochrome) (NN:[560..565] P-450))
      (VP (VBD:[566..569] was)
        (VP (VBN:[570..577] induced)
          (NP-1 (-NONE-:[577..577] *))
          (PP (IN:[579..581] by)
            (NP-LGS (NN:[582..591] hyperoxia)))
          (ADVP (FW:[592..594] in) (FW:[595..600] vitro))
          (PP-LOC (IN:[601..603] in)
            (NP
              (NP (DT:[604..605] a) (NN:[606..616] suspension))
              (PP (IN:[617..619] of)
                (NP (NNS:[620..631] hepatocytes))))))))
    (,:[631..632] ,) (CC:[633..636] and)
    (S
      (NP-SBJ-2 (DT:[637..641] this) (NN:[642..651] induction))
      (VP (VBD:[652..655] was)
        (VP (VBN:[657..666] prevented)
          (NP-2 (-NONE-:[666..666] *))
          (PP
            (PP (IN:[667..669] by)
              (NP-LGS
                (NP (NNS:[670..680] inhibitors))
                (PP (IN:[681..683] of)
                  (NP (NN:[684..697] transcription) (CC:[698..701] and)
                      (NN:[702..713] translation)))))
            (CC:[714..717] and)
            (PP (IN:[718..720] by)
              (NP-LGS (NN:[721..731] disulfiram)))))))
    (.:[731..732] .)))

;sentence 7 Span:734..867
;Cytochrome P-450 induction is not a general phenomenon of stress, albeit 
;physical restraint may decrease the level of P-450 induced.
;[734..750]:cyp450:"Cytochrome P-450"
;[853..858]:cyp450:"P-450"
(SENT
  (S
    (NP-SBJ
      (NML (NN:[734..744] Cytochrome) (NN:[745..750] P-450))
      (NN:[751..760] induction))
    (VP (VBZ:[761..763] is) (RB:[764..767] not)
      (NP-PRD
        (NP (DT:[768..769] a) (JJ:[770..777] general) (NN:[778..788] phenomenon))
        (PP (IN:[789..791] of)
          (NP (NN:[792..798] stress))))
      (,:[798..799] ,)
      (SBAR-ADV (IN:[800..806] albeit)
        (S
          (NP-SBJ (JJ:[808..816] physical) (NN:[817..826] restraint))
          (VP (MD:[827..830] may)
            (VP (VB:[831..839] decrease)
              (NP
                (NP (DT:[840..843] the) (NN:[844..849] level))
                (PP (IN:[850..852] of)
                  (NP
                    (NP (NN:[853..858] P-450))
                    (VP (VBN:[859..866] induced)
                      (NP (-NONE-:[866..866] *)))))))))))
    (.:[866..867] .)))

;sentence 8 Span:868..965
;Induction was a  specific effect of increased oxygen tensions and was not due
;to pressure per se.
;[914..920]:substance:"oxygen"
(SENT
  (S
    (NP-SBJ (NN:[868..877] Induction))
    (VP
      (VP (VBD:[878..881] was)
        (NP-PRD
          (NP (DT:[882..883] a) (JJ:[885..893] specific) (NN:[894..900] effect))
          (PP (IN:[901..903] of)
            (NP (VBN:[904..913] increased) (NN:[914..920] oxygen)
                (NNS:[921..929] tensions)))))
      (CC:[930..933] and)
      (VP (VBD:[934..937] was) (RB:[938..941] not)
        (PP-PRP-PRD (JJ:[942..945] due)
          (PP (TO:[946..948] to)
            (NP
              (NP (NN:[949..957] pressure))
              (ADVP (FW:[958..961] per) (FW:[962..964] se)))))))
    (.:[964..965] .)))

;sentence 9 Span:967..1121
;Neither equivalent pressures of compressed air in the in vivo experiments nor
; equivalent pressures of nitrogen in the in vitro experiments induced P-450.
;[1010..1013]:substance:"air"
;[1070..1078]:substance:"nitrogen"
;[1115..1120]:cyp450:"P-450"
(SENT
  (S
    (NP-SBJ (CC:[967..974] Neither)
      (NP
        (NP (JJ:[975..985] equivalent) (NNS:[986..995] pressures))
        (PP (IN:[996..998] of)
          (NP (VBN:[999..1009] compressed) (NN:[1010..1013] air)))
        (PP (IN:[1014..1016] in)
          (NP (DT:[1017..1020] the)
            (ADJP (FW:[1021..1023] in) (FW:[1024..1028] vivo))
            (NNS:[1029..1040] experiments))))
      (CC:[1041..1044] nor)
      (NP
        (NP (JJ:[1046..1056] equivalent) (NNS:[1057..1066] pressures))
        (PP (IN:[1067..1069] of)
          (NP (NN:[1070..1078] nitrogen)))
        (PP (IN:[1079..1081] in)
          (NP (DT:[1082..1085] the)
            (ADJP (FW:[1086..1088] in) (FW:[1089..1094] vitro))
            (NNS:[1095..1106] experiments)))))
    (VP (VBD:[1107..1114] induced)
      (NP (NN:[1115..1120] P-450)))
    (.:[1120..1121] .)))

;sentence 10 Span:1123..1184
;Induction in vivo was inhibited by disulfiram and metyrapone.
;[1158..1168]:substance:"disulfiram"
;[1173..1183]:substance:"metyrapone"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1123..1132] Induction))
      (ADVP (FW:[1133..1135] in) (FW:[1136..1140] vivo)))
    (VP (VBD:[1141..1144] was)
      (VP (VBN:[1145..1154] inhibited)
        (NP-1 (-NONE-:[1154..1154] *))
        (PP (IN:[1155..1157] by)
          (NP-LGS (NN:[1158..1168] disulfiram) (CC:[1169..1172] and)
                  (NN:[1173..1183] metyrapone)))))
    (.:[1183..1184] .)))

;sentence 11 Span:1185..1316
;Hyperoxia is the  most rapid inducer of P-450 yet found, and this response
;may represent a  protective mechanism against hyperoxia.
;[1225..1230]:cyp450:"P-450"
(SENT
  (S
    (S
      (NP-SBJ (NN:[1185..1194] Hyperoxia))
      (VP (VBZ:[1195..1197] is)
        (NP-PRD
          (NP
            (NP (DT:[1198..1201] the)
              (ADJP (RBS:[1203..1207] most) (JJ:[1208..1213] rapid))
              (NN:[1214..1221] inducer))
            (PP (IN:[1222..1224] of)
              (NP (NN:[1225..1230] P-450))))
          (VP
            (ADVP-TMP (RB:[1231..1234] yet))
            (VBN:[1235..1240] found)
            (NP (-NONE-:[1240..1240] *))))))
    (,:[1240..1241] ,) (CC:[1242..1245] and)
    (S
      (NP-SBJ (DT:[1246..1250] this) (NN:[1251..1259] response))
      (VP (MD:[1260..1263] may)
        (VP (VB:[1264..1273] represent)
          (NP
            (NP (DT:[1274..1275] a) (JJ:[1277..1287] protective)
                (NN:[1288..1297] mechanism))
            (PP (IN:[1298..1305] against)
              (NP (NN:[1306..1315] hyperoxia)))))))
    (.:[1315..1316] .)))

;section 12 Span:1320..1364
;PMID: 7423654 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1320..1324] PMID) (::[1324..1325] :) (CD:[1326..1333] 7423654)
        (NN:[1334..1335] -LSB-) (NNP:[1335..1341] PubMed) (::[1342..1343] -)
        (NN:[1344..1351] indexed) (IN:[1352..1355] for)
        (NNP:[1356..1364] MEDLINE-RSB-)))
